Gavin Stormont
Urology · New Ulm, MNNPI 1639690589
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $879 and has fallen 94.2% since, to $51 in 2025.
Across 97 payments — averaging $33.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$557
- Teleflex LLC$478
- Procept Biorobotics Corporation$407
- Coloplast$246
- Neotract Inc.$233
- Axonics, Inc.$197
- plus $1K from 21 others
Across 1 payment — averaging $100,000 each. An ownership or investment interest held by the physician or an immediate family member.
- Pelvital USA, Inc.$100K
What the payments were for
- Travel & lodging$2738%
- Food & beverage$2,96892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $557 |
| Teleflex LLC | 18 | $478 |
| Procept Biorobotics Corporation | 2 | $407 |
| Coloplast | 8 | $246 |
| Neotract Inc. | 4 | $233 |
| Axonics, Inc. | 5 | $197 |
| Olympus America Inc. | 4 | $154 |
| Johnson & Johnson(2 entities) | 3 | $122 |
| 180 Medical, Inc. | 7 | $120 |
| Accord Healthcare, Inc. | 5 | $82 |
| Photocure Inc | 2 | $72 |
| Astellas Pharma US Inc | 4 | $66 |
| KARL Storz Endoscopy-america | 1 | $65 |
| Antares Pharma, Inc. | 4 | $64 |
| Medtronic | 2 | $55 |
| Novartis | 3 | $54 |
| AbbVie | 3 | $44 |
| Progenics Pharmaceuticals, Inc. | 2 | $44 |
| Convatec Inc. | 3 | $39 |
| Halozyme Inc | 2 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Blue Earth Diagnostics | 1 | $16 |
| Tolmar, Inc. | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| Clinical Technology, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$407
- UroLift System$266
- AMS 700 CXR RTE KIT$231
- Axonics r-SNM System$127
- UroLift$109
How this compares
$3,241 in reported general payments places this provider in the 75th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 79 | $47,212 |
| GemtesaVibegron | 40 | $23,200 |
| Trospium Chloride | 75 | $4,478 |
| Tamsulosin Hcl | 287 | $4,317 |
| Trospium Chloride ErTrospium Chloride | 15 | $2,635 |
| Estradiol | 27 | $2,235 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $1,781 |
| Oxybutynin Chloride ErOxybutynin Chloride | 93 | $1,674 |
| Finasteride | 117 | $1,569 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $817 |
| Oxybutynin Chloride | 11 | $273 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $132 |
| Cephalexin | 15 | $109 |
| Ciprofloxacin Hcl | 17 | $81 |
| Amoxicillin | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $66 | $47,21279 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $16 | $23,20040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 247 urology providers in Minnesota.
Other urology in New Ulm
- David YangMankato$298K
- Steven BernsteinEdina$271K
- Ayman SoubraMinneapolis$204K
- Sean ElliottMinneapolis$163K
- Jonathan WarnerRochester$144K
- Steven SiegelWoodbury$140K
- Aaron MilbankWoodbury$97K
- Tobias KohlerRochester$89K
- Joseph MahonEdina$86K
- Nissrine NakibMinneapolis$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.